Inhibitors of the bone-marrow colony formation in sera of patients with leukemia
✍ Scribed by M. Granström; B. Wahren; G. Gahrton; D. Killander; G. E. Foley
- Publisher
- John Wiley and Sons
- Year
- 1972
- Tongue
- French
- Weight
- 450 KB
- Volume
- 10
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
An increased variation of the bone‐marrow colony stimulating factor (CSF) was found in the sera of patients with acute leukemia as compared to normal sera. In sequential samples from the same patient, there was no apparent correlation between changes in the degree of colony stimulating activity and changes in the clinical and hematologic status. CSF levels as measured in untreated sera seemed to depend upon a variation in serum inhibitor levels. After chloroform treatment, sera from patients with acute lymphoid or myeloid leukemias had higher mean CSF activity than similarly treated normal sera, though the variation was considerable in both groups. The increase was most evident in sera which initially exhibited a normal or low degree of colony‐stimulating activity. In order to evaluate CSF in normal persons and in various diseases, it appears important to remove inhibitory substances efficiently, for instance by chloroform treatment.
📜 SIMILAR VOLUMES
## Abstract ## BACKGROUND Patients with chronic lymphocytic leukemia (CLL) that transforms to Richter syndrome (RS) frequently show atypical lymphocytes in bone marrow; however, a diagnosis of RS requires confirmation of the presence of sheets of large cells in bone marrow or lymph nodes. ## METH
Improved tolerance of splenectomized patients with Hodgkin's disease (HD) to radiotherapy and chemotherapy has been reported. The present study was undertaken to determine the effects of splenectomy and nitrogen mustard (NM) on colony-forming cells (CFC's) of bone marrow cells obtained from CF, male
Objective. Bone marrow stromal cell antigen I (BST-1) is a novel glycosyl phosphatidylinositolanchored ectoenzyme, which is overexpressed on bone marrow stromal and synovial cell lines derived from patients with rheumatoid arthritis (RA). To investigate the pathophysiologic roles of BST-I in RA, we